Alcon Buys Into Eye Disease Drug | Chemical & Engineering News
Volume 90 Issue 13 | p. 27 | Concentrates
Issue Date: March 26, 2012

Alcon Buys Into Eye Disease Drug

Department: Business
Keywords: eye disease, pharmaceuticals

Alcon is paying Belgian biotech firm ThromboGenics $100 million up front for the right to commercialize the eye disease drug ocriplasmin outside the U.S. European regulatory authorities are currently considering the drug as a treatment for symptomatic vitreomacular adhesion, a disease that can cause visual distortion and central blindness. Ocriplasmin is a truncated form of plasmin that is delivered through a one-time injection in the eye.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment